Kunhong Zhong

TL;DR: TanCAR-T cells targeting CD70 and B7-H3 exhibit enhanced antitumor functionality and improve the problem of antigenic heterogeneity and variant in the treatment against solid tumor and melanoma.

TL;DR: In this article , the authors summarize recent advances of major targeted protein degradation (TPD) technologies, discuss their potential applications, and hope to provide a prime for both biologists and chemists who are interested in this vibrant field.

TL;DR: Although B7-H3 represents a promising pan-cancer target, and B7 -H3-redirected CAR-T cells can effectively control tumor growth, the expression heterogeneity and variation have to be carefully considered in translating B 7-H 3-targetedCAR-T cell therapy into clinical practice.

TL;DR: Wang et al. as discussed by the authors developed multivalent nanobodies with high affinity blocking SARS-CoV-2 spike interaction with ACE2 protein, which demonstrated antiviral activity by neutralizing spike pseudotyped viruses in vitro.

TL;DR: It is found that for the first time, B7-H3 was highly and homogeneously expressed in NKTCL cell lines and might be a promising therapeutic target for treating patients withNKTCL tumors.